mTOR inhibition: a double-edged sword in patients with COVID-19?
Hum Cell
; 34(2): 698-699, 2021 Mar.
Article
in English
| MEDLINE | ID: covidwho-1060392
ABSTRACT
The current COVID-19 is one of the deadliest pandemics in recent decades. In the lack of a specific treatment for this novel infection, knowing the role of cell signaling pathways in the pathogenesis of this infection could be useful in finding effective drugs against this disease. The mammalian or mechanistic target of rapamycin (mTOR) is an important cell signaling pathway that has important role in the regulation of cell growth, protein synthesis, and metabolism in reactance to upstream signals in both pathological and normal physiological conditions. Recently, some researchers have suggested the therapeutic potential of mTOR inhibitors such as rapamycin against COVID-19. However, it is important to consider the role of activation of this pathway in controlling immune system response against viral activity in drug repositioning of rapamycin and other mTOR inhibitors in SARS-CoV-2 infection.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Signal Transduction
/
Sirolimus
/
TOR Serine-Threonine Kinases
/
Drug Repositioning
/
COVID-19 Drug Treatment
/
Immune System
Limits:
Humans
Language:
English
Journal:
Hum Cell
Year:
2021
Document Type:
Article
Affiliation country:
S13577-021-00495-2
Similar
MEDLINE
...
LILACS
LIS